Selected article for: "effective vaccine and major challenge"
Author: Halstead, Scott B.
Title: Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development
  • Cord-id: hz5vigp0
  • Document date: 2021_9_9
    • ID: hz5vigp0
    Snippet: Vaccine-associated enhanced disease (VAED) is a serious barrier to attaining successful virus vaccines in human and veterinary medicine. VAED occurs as two different immunopathologies, antibody-dependent enhancement (ADE) and vaccine-associated hypersensitivity (VAH). ADE contributes to the pathology of disease caused by four dengue viruses (DENV) through control of the intensity of cellular infection. Products of virus-infected cells are toxic. A partially protective yellow fever chimeric tetra
    Document: Vaccine-associated enhanced disease (VAED) is a serious barrier to attaining successful virus vaccines in human and veterinary medicine. VAED occurs as two different immunopathologies, antibody-dependent enhancement (ADE) and vaccine-associated hypersensitivity (VAH). ADE contributes to the pathology of disease caused by four dengue viruses (DENV) through control of the intensity of cellular infection. Products of virus-infected cells are toxic. A partially protective yellow fever chimeric tetravalent DENV vaccine sensitized seronegative children to ADE breakthrough infections. A live-attenuated tetravalent whole virus vaccine in phase III testing appears to avoid ADE by providing durable protection against the four DENV. VAH sensitization by viral vaccines occurred historically. Children given formalin-inactivated measles or respiratory syncytial virus (RSV) vaccines experienced severe disease during breakthrough infections. Tissue responses demonstrated that VAH not ADE caused these vaccine safety problems. Subsequently, measles was successfully and safely contained by a live-attenuated virus vaccine. The difficulty in formulating a safe and effective RSV vaccine is troublesome evidence that avoiding VAH is a major research challenge. VAH-like tissue responses were observed during breakthrough homologous virus infections in monkeys given severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS) vaccines.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory infection and ade dengue: 1
    • acute respiratory infection and adjuvant system: 1
    • acute respiratory infection and adjuvant virus: 1, 2
    • acute respiratory infection and live virus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory infection and long duration: 1, 2
    • acute respiratory infection and long short: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory infection and long short period: 1
    • acute respiratory infection and longitudinal study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute respiratory infection and low concentration: 1, 2, 3, 4, 5, 6, 7, 8
    • acute respiratory infection and lps bacterial lipopolysaccharide: 1
    • acute respiratory infection and lung function: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29
    • acute respiratory infection and lung macrophage: 1, 2, 3, 4
    • acute respiratory infection and lung pathology: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory infection and lymph node: 1, 2, 3, 4, 5, 6, 7
    • acute respiratory infection and lymphoid tissue: 1, 2, 3, 4
    • acute respiratory infection cause and longitudinal study: 1
    • acute respiratory infection cause and low concentration: 1
    • acute respiratory infection cause and lung function: 1, 2
    • acute respiratory infection cause and lung pathology: 1